Hikma Pharmaceuticals Plc Total Voting Rights (0644G)
November 01 2018 - 8:39AM
UK Regulatory
TIDMHIK
RNS Number : 0644G
Hikma Pharmaceuticals Plc
01 November 2018
Hikma Pharmaceuticals PLC
Total Voting Rights and Capital
LONDON, 1 November 2018 - In accordance with the UK Financial
Conduct Authority's (the "FCA") DTR 5.6.1, Hikma Pharmaceuticals
PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK)
notifies the market that as at 31 October 2018, its share capital
consists of 241,445,043 ordinary shares with voting rights. There
are nil shares held in treasury.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, Hikma Pharmaceuticals PLC under the FCA's DTR's.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2760
About Hikma
Hikma helps puts better health within reach every day for
millions of people in more than 50 countries around the world. For
40 years, we've been creating high-quality medicines and making
them accessible to the people who need them. We're a global company
with a local presence across the United States (US), the Middle
East and North Africa (MENA) and Europe, and we use our unique
insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,500 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner in
the MENA region, and through our venture capital arm, are helping
bring innovative health technologies to people around the world.
For more information, please visit www.hikma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVREAAFFEDNPFFF
(END) Dow Jones Newswires
November 01, 2018 08:39 ET (12:39 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2024 to Aug 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Aug 2023 to Aug 2024